Giulio Draetta

Giulio Draetta, M.D., Ph.D., is an Advisor at Helsinn Investment Fund. scientific advisor of Blueprint Medicines.Dr. Draetta is currently the Chief Scientific Officer at The University of Texas MD Anderson Cancer Center. He was the former Chief Research Business Development Officer, Dana Farber Cancer Institute; Former Deputy Director, Belfer Institute for Applied Cancer Science at DFCI. A Former head of oncology drug discovery at Pharmacia and Merck. Scientific Advisor: Epitherapeutics, Forma Therapeutics, Blueprint Medicines, Taiho Pharmaceutical Co.

While at Cold Spring Harbor Laboratory, at EMBL Heidelberg and the European Institute of Oncology, Dr. Draetta spearheaded fundamental research in the biology of the eukaryotic cell division cycle and of DNA damage induced checkpoints. He was co-founder and head of research of Mitotix, Inc. At Pharmacia and Merck where he focused on the discovery and development of inhibitors of receptor tyrosine kinase signaling, cell division cycle inhibitors, novel cytotoxics, developmental pathway inhibitors, epigenetics, and cancer metabolism drugs.

Giulio Draetta is the Chairman & Scientific Advisory Board at Karyopharm Therapeutics, based in United States, North America. With a background in Health Care, Giulio Draetta has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.